The importance of intratumour genetic and functional heterogeneity is increasingly recognised
as a driver of cancer progression and survival outcome. Understanding how tumour …

PURPOSE: CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic
breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized …

Background There is a considerable body of pre-clinical, epidemiological and randomised
data to support the hypothesis that aspirin has the potential to be an effective adjuvant cancer …

High-quality randomised clinical trials testing moderately fractionated breast radiotherapy
have clearly shown that local control and survival is at least as effective as with 2 Gy daily …

Background Pre-clinical models demonstrate that platelet activation is involved in the spread
of malignancy. Ongoing clinical trials are assessing whether aspirin, which inhibits platelet …

Background Preclinical, epidemiological, and randomised data indicate that aspirin might
prevent tumour development and metastasis, leading to reduced cancer mortality, particularly …

Objectives Aspirin could be offered for colorectal cancer prevention for the UK general
population. To ensure the views of the general population are considered in future guidance, we …

Background The National Institute for Health and Care Excellence (NG151) recommends
considering daily aspirin for people with Lynch syndrome to reduce colorectal cancer risk. …

Introduction Breast reconstruction (BR) is offered to improve quality of life for women with
breast cancer undergoing mastectomy. As most women will be long-term breast cancer …

Clinical trials provide the opportunity to collect biological samples for translational research
in a defined patient population with uniform and detailed follow-up. In the past, these have …